Latest Venlafaxine Stories
WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's long-term efficacy in preventing recurrence of depressive mood episodes in patients who suffer from major depressive disorder, is the attribute that most influences psychiatrists' prescribing decisions in the treatment of this disorder.
By John Sullivan, The Philadelphia Inquirer Jul. 11--Patients taking a popular type of antidepressant are at greater risk for upper gastrointestinal bleeding, according to a new study which appears in the July issue of Archives of General Psychiatry.
The U.S. Food and Drug Administration is expected Thursday to recommend black-box warnings on suicide risk for 11 epilepsy drugs.
PT. RICHMOND, Calif., July 2 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced the appointment of Terrence Moore to the position of Vice President, Marketing and Sales and Susan Koppy to the position of Vice President, Corporate Development. Both Mr. Moore and Ms.
Mylan has announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the FDA for its abbreviated new drug application for Venlafaxine hydrochloride tablets 25mg, 37.5mg, 50mg, 75mg and 100mg.
WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, despite physicians' desire to prescribe more serotonin/norepinephrine reuptake inhibitors (SNRIs), Forest Laboratories' Lexapro retains leadership among first-line therapies in the treatment of major depression.
A new study by scientists in the U.S., Canada and Britain has called into question the effectiveness of anti-depressant medications, including the popular Prozac and Paxil.
The termination of Pristiq for fibromyalgia represents another setback for Wyeth, which had high hopes for its follow-on drug to Effexor.
Authors of a new comprehensive analysis of antidepressants for children and teenagers say the benefits of treatment trump the small risk of increasing some patients' chances of having suicidal thoughts and behaviors.
Information about risks to newborns and migraine sufferers linked to some of the world's most widely used antidepressants should be added to the drug labels, the U.S. Food and Drug Administration said on Wednesday.